Prompt action by Alabama rheumatologists has caused Blue Cross Blue Shield to rethink a policy denying all claims for injections into knees with osteoarthritis. But a similar "ban" on hyaluronic acid in neighboring Florida takes effect today.
A second biomarker panel shows promise in distinguishing osteoarthritis from rheumatoid arthritis early enough to prevent joint damage. This one relies partly on lack of antibody response to citrullinated proteins in early osteoarthritis.
Pfizer and Lilly will resume development of the anti-nerve growth factor monoclonal antibody tanezumab for osteoarthritis pain, after the FDA lifted its ban imposed due to adverse effects in animal trials.
The good news: At best, intraarticular hyaluronate injected into the knee for osteoarthritis (OA) is modestly effective. The bad news: At worst, it’s indistinguishable from placebo, in some meta-analyses.